SynthesisFrontiers in immunology2025

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials.

Yuxuan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.